Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Gregory Schwartz , P. Gabriel Steg , Michael Szarek , Deepak Bhatt (1) , Vera Bittner , Rafael Díaz (2) , Jay Edelberg , Shaun Goodman , Corinne Hanotin , Robert Harrington , J. Wouter Jukema (3) , Guillaume Lecorps (4) , Kenneth Mahaffey , Angèle Moryusef , Robert Pordy , Kirby Quintero , Matthew Roe , William Sasiela , Jean-François Tamby , Pierluigi Tricoci , Harvey White , Andreas Zeiher , Jacques Mansourati (5)

1 VA Boston Healthcare System
2 Department of General Surgery. Surgical Oncology Unit
3 Metacohorts Consortium
4 Sanofi [Vitry-sur-Seine]
5 CIC Brest

Domaines: Sciences du Vivant [q-bio]; Médecine humaine et pathologie; Cardiologie et système cardiovasculaire

Gregory Schwartz, P. Gabriel Steg, Michael Szarek, Deepak Bhatt, Vera Bittner, et al.. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 2018, 379 (22), pp.2097-2107. ⟨10.1056/NEJMoa1801174⟩. ⟨hal-02059074⟩